Literature DB >> 17607118

Impact of induction treatment on postoperative complications in the treatment of non-small cell lung cancer.

Laurent Brouchet1, Eric Bauvin, Bertrand Marcheix, Laurence Bigay-Game, Claire Renaud, Jean Berjaud, Pierre Emmanuel Falcoze, Nicolas Venissac, Dan Raz, David Jablons, Julien Mazières, Marcel Dahan.   

Abstract

INTRODUCTION: A main drawback of neoadjuvant chemotherapy is that it may increase operative morbidity and mortality. The aim of this study was to determine the impact of chemotherapy on these complications.
METHODS: Patient data were collected from the Epithor database. From June 2002 to June 2004, 3888 successive observations of surgery for lung cancer have been reported from 51 thoracic surgery departments throughout France. Logistic regression analysis was performed to identify preoperative clinical characteristics of patients with significant postoperative complications.
RESULTS: Of 3888 patients, 555 (14.3%) received induction chemotherapy. The groups were similar with respect to sex and the number of comorbidities. The in-hospital mortality rate was 3.01%. The multivariate analysis allows us to identify age (older than 65 years), sex (male), preoperative clinical score (moderate and severe), surgical procedure (right pneumonectomy and bilobectomy) as significantly associated with in-hospital mortality. No statistical difference was observed according to the delivery or preoperative chemotherapy. In total, 1219 patients (31.4%) had at least one postoperative complication. Using a multivariate analysis, we observed a significant correlation between morbidity and age (older than 65 years), sex (male), presence of comorbidities (two or more), clinical score (moderate), and type of operation (bilobectomy). Preoperative administration of chemotherapy did not significantly influenced postoperative morbidity.
CONCLUSIONS: Preoperative chemotherapy is not associated with an increase in either the mortality rate or major surgical complications. Future randomized trials are warranted to confirm the survival benefit of this strategy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17607118     DOI: 10.1097/JTO.0b013e318074bbe2

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  5 in total

1.  Thoracoscopic surgery for pulmonary metastases after chemotherapy using a tailor-made virtual lung.

Authors:  Tadashi Akiba; Hideki Marushima; Noriteru Kamiya; Makoto Odaka; Satoki Kinoshita; Hiroshi Takeyama; Toshiaki Morikawa
Journal:  Gen Thorac Cardiovasc Surg       Date:  2011-06-15

2.  A Phase 1 Study of Concurrent Neoadjuvant Pembrolizumab Plus Chemoradiation Followed by Consolidation Pembrolizumab in Patients With Resectable Stage IIIA NSCLC.

Authors:  Christopher A Lemmon; Gregory M M Videtic; Sudish Murthy; Kevin L Stephans; Marc Shapiro; Usman Ahmad; Daniel Raymond; Vamsidhar Velcheti; Alejandro Bribriesco; Xuefei Jia; James Stevenson; Nathan A Pennell
Journal:  JTO Clin Res Rep       Date:  2022-06-15

3.  Sleeve lobectomy and pneumonectomy: can they really be properly compared?

Authors:  Ramón Rami-Porta; Sergi Call
Journal:  Transl Lung Cancer Res       Date:  2020-06

Review 4.  [Progress of Neoadjuvant Therapy Combined with Surgery in Non-small Cell
Lung Cancer].

Authors:  Yaqi Wang; Xing Wang; Shi Yan; Yue Yang; Nan Wu
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2017-05-20

5.  Comparison of postoperative complications in advanced head and neck cancer patients receiving neoadjuvant chemotherapy followed by surgery versus surgery alone.

Authors:  Poonam Joshi; Amit Joshi; Kumar Prabhash; Vanita Noronha; Pankaj Chaturvedi
Journal:  Indian J Med Paediatr Oncol       Date:  2015 Oct-Dec
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.